BUCHAN CONSULTING PTY LTD
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Prota Therapeutics' CEO Mimi Tang honoured at BioMelbourne Network's Women in Leadership Awards 2024 2024-04-29 19:25
Prota Therapeutics' CEO Mimi Tang honoured at BioMelbourne Network's Women in Leadership Awards 2024 2024-04-29 10:40
Trajan's Microsampling Devices Meet IVDR Compliance in Europe, UK 2023-06-02 20:00
Appendix 4C - Q2 FY23 Quarterly Cash Flow Report 2023-01-31 20:25
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy 2023-01-09 23:25
Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation) 2023-01-06 20:25
Alterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum 2023-01-03 23:25
Alterity Therapeutics Announces Allowance of New Composition of Matter Patent by the United States Patent and Trademark Office 2022-12-29 23:25
Alterity Therapeutics Announces Presentation of Data from the bioMUSE Natural History Study at the American Autonomic Society Annual Meeting 2022-11-07 23:25
Alterity Therapeutics Announces Presentation of MRI Data from the bioMUSE Natural History Study at the American Neurological Association Annual Meeting 2022-10-26 19:25
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Australia for the Treatment of Individuals with Multiple System Atrophy 2022-10-13 22:25
Alterity Therapeutics Announces Presentation of Wearable Sensor Data from the bioMUSE Natural History Study at the International Congress of Parkinson's Disease and Movement Disorders 2022-09-26 19:25
Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy 2022-09-20 19:25
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe 2022-08-25 19:25
Alterity Therapeutics: Appendix 4C - Q4 FY22 Quarterly Cash Flow Report 2022-07-22 19:25
Alterity Therapeutics Doses First Patient in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy 2022-07-06 23:00
Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy 2022-06-23 23:00
Trajan to acquire leading chromatography consumables and tools business building critical mass in the gas chromatography portfolio 2022-06-19 22:15
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy 2022-06-02 20:00
Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom 2022-04-27 19:40
1 2 3 4